Why Humira’s patent dispute lasted beyond its first patent
Humira is a biologic: a medicine made from living cells, rather than a small molecule assembled through ordinary chemical reactions. That distinction matters when competitors try to make a lower-cost version. A biologic is difficult to copy exactly, so rivals generally seek approval for a biosimilar—a medicine shown to be highly similar and to work in much the same way—not a conventional generic.
The original patent on a drug does not have to be the last one relevant to its commercial life. Companies can also patent later inventions involving a medicine’s formulation, delivery device, dosing, or manufacturing. Each patent has its own claims and expiration date. Taken together, overlapping patents can make it costly and risky for a competitor to launch, even after the earliest patent has expired.
How a patent thicket creates leverage
A biosimilar maker may have to assess many patents and decide which claims to challenge, negotiate around, or contest in court. A lawsuit over one patent does not automatically prove that the competitor infringed it; nor does a large patent portfolio establish that every patent is valid. But the prospect of years of litigation, potential damages, and delayed market entry can shape a company’s choices before a judge resolves every dispute.
That is the economic force of a patent thicket: not necessarily a single barrier that makes competition impossible, but a layered set of legal risks that can raise the cost of challenging an incumbent. AbbVie defended Humira with a large portfolio of patents, and disputes with biosimilar makers ended in settlements that set dates for US launches. Several competitors entered the US market in 2023, rather than launching as soon as the original patent expired.
What the delay meant—and what it did not
The strategy extended Humira’s period without US biosimilar competition, but it did not create an unbreakable monopoly. Once competitors could enter, they still faced the practical work of producing a complex medicine, winning approval, and persuading healthcare buyers to switch. And a lower-priced biosimilar does not automatically translate into an equal savings for every patient; insurance coverage and purchasing arrangements affect what people pay.
The lasting consequence is a distinction between when a drug’s first patent ends and when competition actually arrives. For biologics, that gap can depend on scientific hurdles and a crowded patent landscape as much as on the original invention.
